VOC Diagnostic Platform

About BioVectis

BioVectis operates as a hybrid company, combining a tools-and-platform business with internal therapeutic/diagnostic R&D. Its flagship DNA Pointer System offers unparalleled temperature-controlled native electrophoresis, serving as a critical research tool for academia and pharma in studying molecular interactions and genetic heterogeneity. Alongside this platform, BioVectis is developing several proprietary programs, including an autoimmune disease therapy (Appus), a recombinant poultry vaccine (Scutum N), and diagnostic platforms for volatile organic compounds (VOC) and biological age estimation. The company appears to be a privately-held, revenue-generating entity leveraging its proprietary technology for both product sales and collaborative research.

Therapeutic Areas